

Guideline: Colorectal Cancer (CRC) (update) Committee meeting 9

Date: 18th and 19th December 2018 (2 days)

Location: RCOG offices, London

Minutes: Final

Day 1: 18th December 2018

Committee members present:	
Peter Hoskin (Chair)	(Present for notes 1–6)
Justin Davies (Topic Adviser)	(Present for notes 1–6)
Cindy Chew	(Present for notes 1–6)
Julie Hepburn	(Present for notes 1–6)
Vivek Misra	(Present for notes 1–6)
Jay Bradbury	(Present for notes 1–6)
Richard Roope	(Present for notes 1–6)
Kevin Monahan	(Present for notes 1–6)
Ratan Verma	(Present for notes 1–6)
Michael Braun	(Present for notes 1–6)
Baljit Singh	(Present for notes 1–6)
Charlotte Dawson	(Present for notes 1–6)
Stephen Fenwick (Co-optee)	(Present for notes 1–6)
Michael Shackcloth (Co-optee)	(Present for notes 1–6)

In attendance:		
Lisa Boardman	NGA Guideline Lead	(Present for notes 1–6)
Palida Teelucknavan	NGA Project Manager	(Present for notes 1–6)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 1–6)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for notes 1–6)
Maija Kalioinen	NGA Systematic Reviewer	(Present for notes 1–6)
Audrey Tan	NGA Systematic Reviewer	(Present for notes 1–6)
Justine Karpusheff	NICE Guideline Commissioning Manager	(Present for notes 1–6)

Apologies:	
Debby Lennard	GC member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 9th meeting on Colorectal Cancer guideline (update). The Committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included: Economic modelling for RQ4.3b; reviewing the evidence and drafting recommendations for RQs 3.6, 4.3b1, 4.3b2 and 6.1.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Stephen Fenwick	Co-opted committee member (Hepatobiliary surgeon)	Funded to attend ECIO conference and paid homorarium to lead session on DEBIRI beads	Indirect, financial	
Richard Roope	Committee member (GP)	Scientific Board for Oncimmune (Oncimmune Holdings PLC profiles the body's immune response to dectect cancers earlier)	Direct, non- financial	
Baljit Singh	Committee member (Colorectal Surgeon)	Chair of the East Midlands Cancer Alliance Group	Direct, non- financial	
Vivek Misra	Committee member (Oncologist)	Gave a lecture on International controversies in rectal cancer which was organised by ICENI	Direct, non- financial	
Cindy Chew	Committee member (Radiologist)	Hospital Sub-Dean for Glasgow University and Hairmyres Hospital	Indirect, financial	

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

3. Presentations

The Chair introduced Matthew Prettyjohns, NGA Senior Health Economist, who gave a presentation on Economic modelling for Review Question 3.6 'What is the optimal surgical technique for rectal cancer?'

The Committee then discussed the issues presented in relation to this guideline. The

Chair thanked Matthew Prettyjohns for their presentation.

The Chair introduced Maija Kallioinen, NGA Systematic Reviewer, who gave a presentation on Review Question 4.3b1 'What is the optimal combination and sequence of treatments in patients presenting with metastatic colorectal cancer in the liver amenable to local treatment?' and Review Question 4.3b2 'What is the optimal combination and sequence of treatments in patients presenting with metastatic colorectal cancer in the liver not amenable to local treatment?'

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Maija Kallioinen for their presentation.

The Chair introduced Matthew Prettyjohns, NGA Senior Health Economist, who gave a presentation on the Economic modelling for Review Questions 4.3b1 and 4.3b2.

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Matthew Prettyjohns for their presentation.

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, who gave a presentation on Economic modelling for Review Question 6.1 'Is there a relationship between surgical volumes and outcomes in the treatment of rectal cancer (primary and recurrent disease)?'

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Nathan Bromham for their presentation.

4. Questions and discussion

The Committee discussed each presentation in relation to this guideline and were given the opportunity to ask questions.

The Committee drafted recommendations based on the evidence heard.

5. Any other business

There was no other business.

Date of next meeting: 19th December 2018

Location of next meeting: RCOG, London

Guideline: Colorectal Cancer (CRC) (update) Committee meeting 9

Date: 18th and 19th December 2018 (2 days)

Location: RCOG offices, London

Minutes: Draft

Day 2: 19th December 2018

Committee members present:	
Peter Hoskin (Chair)	(Present for notes 1–5)
Justin Davies (Topic Adviser)	(Present for notes 1–5)
Cindy Chew	(Present for notes 1–5)
Julie Hepburn	(Present for notes 1–5)
Vivek Misra	(Present for notes 1–5)
Jay Bradbury	(Present for notes 1–5)
Richard Roope	(Present for notes 1–5)
Kevin Monahan	(Present for notes 1–5)
Ratan Verma	(Present for notes 1–5)
Michael Braun	(Present for notes 1–5)
Baljit Singh	(Present for notes 1–5)
Charlotte Dawson	(Present for notes 1–5)
Stephen Fenwick (Co-optee)	(Present for notes 1–5)
Michael Shackcloth (Co-optee)	(Present for notes 1–5)
Faheez Mohamed (Co-optee)	(Present for notes 1–5)

In attendance:		
Lisa Boardman	NGA Guideline Lead	(Present for notes 1–5)
Palida Teelucknavan	NGA Project Manager	(Present for notes 1–5)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for notes 1–5)
Maija Kalioinen	NGA Systematic Reviewer	(Present for notes 1–5)
Audrey Tan	NGA Systematic Reviewer	(Present for notes 1–5)
Agnesa Mehmeti	NGA Information Scientist	(Present for notes 1–5)
Stephen Pilling	NGA Clinical Adviser	(Present for notes 1–5)
Justine Karpusheff	NICE Guideline Commissioning Manager	(Present for notes 1–5)

Apologies:	
Debby Lennard	GC member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 9th meeting on Colorectal Cancer guideline (update). The Committee members and attendees introduced themselves.

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included: A guideline stocktake; review of NICE feedback on draft recommendations and rational and impact sections so far; review of the evidence and drafting recommendations for RQs 4.3a and 4.3c; updated protocol for RQ3.8.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

There were no new declarations of interest.

3. Presentations

The Chair introduced Lisa Boardman, NGA Guideline Lead, who led a discussion on a stocktake of the guideline and also presented feedback from the NICE Editor on the recommendations drafted to date.

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Lisa Boardman for their contribution.

The Chair introduced Audrey Tan, NGA Systematic Reviewer, who gave a presentation on Review Question Review 4.3a 'What is the optimal combination and sequence of treatments in patients presenting with metastatic colorectal cancer in the lung amenable to local treatment?' and Review Question 4.3c 'What is the optimal combination and sequence of local and systemic treatments in patients presenting with metastatic colorectal cancer isolated in the peritoneum?'

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Audrey Tan for their presentation.

The Chair introduced Maija Kallioinen, NGA Systematic Reviewer, who gave a presentation on the updated protocol for 3.8 'What is the effectiveness of stenting followed by planned elective bowel resection compared with emergency bowel resection for suspected colorectal cancer causing acute large bowel obstruction?'

The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Maija Kallioinen for their presentation.

4. Questions and discussion

The Committee discussed each presentation in relation to this guideline and were given the opportunity to ask questions.

The Committee drafted recommendations based on the evidence heard.

5. Any other business

There was no other business.

Date of next meeting: 14th February 2019

Location of next meeting: RCOG, London